Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 29, 2024

SELL
$47.98 - $54.4 $13,386 - $15,177
-279 Reduced 11.04%
2,248 $121,000
Q4 2023

Feb 21, 2024

BUY
$48.48 - $57.85 $23,609 - $28,172
487 Added 23.87%
2,527 $130,000
Q3 2023

Nov 17, 2023

SELL
$57.89 - $64.73 $385,836 - $431,425
-6,665 Reduced 76.57%
2,040 $118,000
Q2 2023

Aug 28, 2023

BUY
$63.71 - $70.74 $426,857 - $473,957
6,700 Added 334.16%
8,705 $557,000
Q1 2023

May 24, 2023

SELL
$65.71 - $74.53 $20,501 - $23,253
-312 Reduced 13.47%
2,005 $139,000
Q4 2022

Feb 24, 2023

BUY
$68.48 - $81.09 $21,365 - $25,300
312 Added 15.56%
2,317 $167,000
Q2 2022

Aug 23, 2022

SELL
$72.62 - $79.98 $3,703 - $4,078
-51 Reduced 2.48%
2,005 $154,000
Q1 2022

May 27, 2022

SELL
$61.48 - $73.72 $92,158 - $110,506
-1,499 Reduced 42.17%
2,056 $150,000
Q4 2021

Feb 25, 2022

SELL
$53.63 - $62.52 $8,956 - $10,440
-167 Reduced 4.49%
3,555 $222,000
Q2 2021

Aug 19, 2021

SELL
$61.91 - $67.42 $25,816 - $28,114
-417 Reduced 10.07%
3,722 $249,000
Q1 2021

May 24, 2021

SELL
$59.34 - $66.74 $59,340 - $66,740
-1,000 Reduced 19.46%
4,139 $261,000
Q4 2020

Feb 26, 2021

BUY
$57.74 - $65.43 $92,384 - $104,688
1,600 Added 45.21%
5,139 $318,000
Q3 2020

Nov 17, 2020

SELL
$57.43 - $63.64 $2,412 - $2,672
-42 Reduced 1.17%
3,539 $213,000
Q2 2020

Sep 02, 2020

BUY
$54.82 - $64.09 $196,310 - $229,506
3,581 New
3,581 $211,000
Q4 2018

Feb 20, 2019

SELL
$48.76 - $63.23 $196,795 - $255,196
-4,036 Closed
0 $0
Q3 2018

Nov 19, 2018

SELL
$55.19 - $62.25 $43,324 - $48,866
-785 Reduced 16.28%
4,036 $215,000
Q1 2018

May 16, 2018

BUY
$59.92 - $68.98 $288,874 - $332,552
4,821 New
4,821 $305,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Garde Capital, Inc. Portfolio

Follow Garde Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Garde Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Garde Capital, Inc. with notifications on news.